A review of the epidemiological profile of patients with atrial fibrillation and heart failure

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 9, 2012, Pages 1133-1140

  Fabbri, Gianna ^a   Maggioni, Aldo P ^a  

^a ANMCO RESEARCH CENTER   (Italy)

Author keywords

atrial fibrillation; clinical trials; epidemiology; heart failure; observational studies; prognosis; rhythm and rate control strategies

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; VALSARTAN; WARFARIN;

CEREBROVASCULAR ACCIDENT; COMORBIDITY; DEFIBRILLATOR; DISEASE ASSOCIATION; FOLLOW UP; HEALTH CARE QUALITY; HEART ATRIUM FIBRILLATION; HEART EJECTION FRACTION; HEART FAILURE; HEART RATE; HUMAN; HYPERTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; OBSERVATIONAL STUDY; PROGNOSIS; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; HEART FAILURE; HUMANS; PREVALENCE; PROGNOSIS; RECURRENCE; RISK FACTORS;

EID: 84867930856     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.12.110     Document Type: Review

References (61)

1. Smith JG, Newton-Cheh C, Almgren P et al. Assessment of conventional cardiovascular risk factors and multiple biomarkers for the prediction of incident heart failure and atrial fibrillation. J. Am. Coll. Cardiol. 56(21), 1712-1719 (2010)
2. Kirchhof P, Lip GY, Van Gelder IC et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options - a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. Europace 14(1), 8-27 (2012)
3. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N. Engl. J. Med. 337(19), 1360-1369 (1997) (Pubitemid 27467771)
4. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 271(11), 840-844 (1994)
5. Lloyd-Jones DM, Larson MG, Leip EP et al.; Framingham Heart Study. Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 106(24), 3068-3072 (2002) (Pubitemid 35440290)
6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N. Engl. J. Med. 325, 293-302 (1991)
7. The CONSENSUS Trial Study Group. Effect of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival study (CONSENSUS) N. Engl. J. Med. 316, 1429-1435 (1987)
8. Fonarow GC, Peacock WF, Phillips CO, Givertz MM, Lopatin M; ADHERE Scientific Advisory Committee and Investigators. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J. Am. Coll. Cardiol. 49(19), 1943-1950 (2007) (Pubitemid 46694287)
9. Lenzen MJ, Scholte op Reimer WJ, Boersma E et al. Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey. Eur. Heart J. 25(14), 1214-1220 (2004) (Pubitemid 38891571)
10. McMurray JJ, Carson PE, Komajda M et al. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial. Eur. J. Heart Fail. 10(2), 149-156 (2008) (Pubitemid 351227428)
11. Maggioni AP, Dahlström U, Filippatos G et al.; Heart Failure Association of ESC (HFA) EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot) Eur. J. Heart Fail. 12(10), 1076-1084 (2010)
12. Mountantonakis SE, Grau-Sepulveda MV, Bhatt DL, Hernandez AF, Peterson ED, Fonarow GC. Presence of atrial fibrillation is independently associated with adverse outcomes in patients hospitalized with heart failure: an analysis of get with the guidelines - heart failure. Circ. Heart Fail. 5(2), 191-201 (2012)
13. Olesen JB, Fauchier L, Lane DA, Taillandier S, Lip GY. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. Chest 141(1), 147-153 (2012)
14. Camm AJ, Kirchhof P, Lip GY et al.; European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) Eur. Heart J. 31 19 2369-2429 2010
15. Baldasseroni S, Orso F, Fabbri G et al.; Italian Network on Congestive Heart Failure Investigators. Age-dependent prognostic significance of atrial fibrillation in outpatients with chronic heart failure: data from the Italian Network on Congestive Heart Failure Registry. Cardiology 116(2), 79-88 (2010)
16. Maggioni AP, Latini R, Carson PE et al.; Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT) Am. Heart J. 149(3), 548-557 (2005) (Pubitemid 40585420)
17. van Veldhuisen DJ, Aass H, El Allaf D et al.; MERIT-HF Study Group. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. Eur. J. Heart Fail. 8(5), 539-546 (2006)
18. Mamas MA, Caldwell JC, Chacko S, Garratt CJ, Fath-Ordoubadi F, Neyses L. A meta-analysis of the prognostic significance of atrial fibrillation in chronic heart failure. Eur. J. Heart Fail. 11(7), 676-683 (2009)
19. Køber L, Swedberg K, McMurray JJ et al. Previously known and newly diagnosed atrial fibrillation: a major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur. J. Heart Fail. 8(6), 591-598 (2006) (Pubitemid 44604352)
20. Olsson LG, Swedberg K, Ducharme A et al.; CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity (CHARM) program. J. Am. Coll. Cardiol. 47(10), 1997-2004 (2006)
21. Maggioni AP, Fabbri G, Lucci D et al.; GISSI-HF Investigators. Effects of rosuvastatin on atrial fibrillation occurrence: ancillary results of the GISSI-HF trial. Eur. Heart J. 30(19), 2327-2336 (2009)
22. Vermes E, Tardif JC, Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 107(23), 2926-2931 (2003) (Pubitemid 36736634)
23. Kirchhof P, Bax J, Blomstrom-Lundquist C et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNETEHRA consensus conference 'research perspectives in AF'. Eur. Heart J. 30(24), 2969-2977 (2009)
24. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 100(4), 376-380 (1999) (Pubitemid 29362407)
25. Anand K, Mooss AN, Hee TT, Mohiuddin SM. Meta-analysis: inhibition of reninangiotensin system prevents new-onset atrial fibrillation. Am. Heart J. 152(2), 217-222 (2006) (Pubitemid 44093401)
26. The ACTIVE-I Investigators. Irbesartan in patients with atrial fibrillation. N. Engl. J. Med. 364, 928-938 (2011)
27. The GISSI-AF Investigators. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 360, 1606-1617 (2009)
28. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by b-blocker treatment in heart failure: a meta-analysis. Eur. Heart J. 28(4), 457-462 (2007) (Pubitemid 47343566)
29. Flather MD, Shibata MC, Coats AJ et al.; SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS) Eur. Heart J. 26(3), 215-225 (2005) (Pubitemid 40222359)
30. Skanes AC, Healey JS, Cairns JA et al.; Canadian Cardiovascular Society Atrial Fibrillation Guidelines Committee. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can. J. Cardiol. 28(2), 125-136 (2012)
31. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 33, 1787-1847 (2012)
32. Piccini JP, Hernandez AF, Zhao X et al.; Get With The Guidelines Steering Committee and Hospitals. Quality of care for atrial fibrillation among patients hospitalized for heart failure. J. Am. Coll. Cardiol. 54(14), 1280-1289 (2009)
33. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 356(9244), 1789-1794 (2000)
34. Carlsson J, Miketic S, Windeler J et al.; STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J. Am. Coll. Cardiol. 41(10), 1690-1696 (2003) (Pubitemid 36584236)
35. Opolski G, Torbicki A, Kosior D et al. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study. Kardiol. Pol. 59(7), 1-16; discussion 15 (2003)
36. Van Gelder IC, Hagens VE, Bosker HA et al.; Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N. Engl. J. Med. 347(23), 1834-1840 (2002) (Pubitemid 35417774)
37. Wyse DG, Waldo AL, DiMarco JP et al.; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N. Engl. J. Med. 347(23), 1825-1833 (2002) (Pubitemid 35417773)
38. Roy D, Talajic M, Nattel S et al.; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N. Engl. J. Med. 358(25), 2667-2677 (2008) (Pubitemid 351860859)
39. Lubitz SA, Fischer A, Fuster V. Catheter ablation for atrial fibrillation. BMJ 336(7648), 819-826 (2008) (Pubitemid 351548225)
40. Shelton RJ, Clark AL, Goode K et al. A randomised, controlled study of rate versus rhythm control in patients with chronic atrial fibrillation and heart failure (CAFE-II Study) Heart 95(11), 924-930 (2009)
41. Wilton SB, Fundytus A, Ghali WA et al. Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patients with versus without left ventricular systolic dysfunction. Am. J. Cardiol. 106(9), 1284-1291 (2010)
42. Khan MN, Jaïs P, Cummings J et al.; PABA-CHF Investigators. Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N. Engl. J. Med. 359(17), 1778-1785 (2008)
43. Chen MS, Marrouche NF, Khaykin Y et al. Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function. J. Am. Coll. Cardiol. 43(6), 1004-1009 (2004) (Pubitemid 38352980)
44. Cleland JG, Daubert JC, Erdmann E et al.; Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. 352(15), 1539-1549 (2005) (Pubitemid 40517094)
45. Beshai JF, Grimm RA, Nagueh SF et al.; RethinQ Study Investigators. Cardiacresynchronization therapy in heart failure with narrow QRS complexes. N. Engl. J. Med. 357(24), 2461-2471 (2007) (Pubitemid 350272785)
46. Gasparini M, Auricchio A, Regoli F et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression: the importance of performing atrioventricular junction ablation in patients with atrial fibrillation. J. Am. Coll. Cardiol. 48(4), 734-743 (2006) (Pubitemid 44175735)
47. Ganesan AN, Brooks AG, Roberts- Thomson KC, Lau DH, Kalman JM, Sanders P. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure: a systematic review. J. Am. Coll. Cardiol. 59(8), 719-726 (2012)
48. Linde C, Leclercq C, Rex S et al. Longterm benefits of biventricular pacing in congestive heart failure: results from the MUltisite STimulation in cardiomyopathy (MUSTIC) study. J. Am. Coll. Cardiol. 40(1), 111-118 (2002) (Pubitemid 34701385)
49. Crijns HJ, Tjeerdsma G, de Kam PJ et al. Prognostic value of the presence and development of atrial fibrillation in patients with advanced chronic heart failure. Eur. Heart J. 21(15), 1238-1245 (2000) (Pubitemid 30487771)
50. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure. A study of 390 patients. Circulation 84(1), 40-48 (1991)
51. Stevenson WG, Stevenson LW, Middlekauff HR et al. Improving survival for patients with atrial fibrillation and advanced heart failure. J. Am. Coll. Cardiol. 28(6), 1458-1463 (1996) (Pubitemid 26391850)
52. Corell P, Gustafsson F, Schou M, Markenvard J, Nielsen T, Hildebrandt P. Prevalence and prognostic significance of atrial fibrillation in outpatients with heart failure due to left ventricular systolic dysfunction. Eur. J. Heart Fail. 9(3), 258-265 (2007) (Pubitemid 46330140)
53. Mahoney P, Kimmel S, DeNofrio D, Wahl P, Loh E. Prognostic significance of atrial fibrillation in patients at a tertiary medical center referred for heart transplantation because of severe heart failure. Am. J. Cardiol. 83(11), 1544-1547 (1999) (Pubitemid 29250037)
54. Pai RG, Varadarajan P. Prognostic significance of atrial fibrillation is a function of left ventricular ejection fraction. Clin. Cardiol. 30(7), 349-354 (2007) (Pubitemid 47122670)
55. Banerjee A, Taillandier S, Olesen JB et al. Ejection fraction and outcomes in patients with atrial fibrillation and heart failure: the Loire Valley Atrial Fibrillation Project. Eur. J. Heart Fail. 14(3), 295-301 (2012)
56. Swedberg K, Olsson LG, Charlesworth A et al. Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with b-blockers: results from COMET. Eur. Heart J. 26(13), 1303-1308 (2005) (Pubitemid 41435461)
57. Carson PE, Johnson GR, Dunkman WB, Fletcher RD, Farrell L, Cohn JN. The influence of atrial fibrillation on prognosis in mild to moderate heart failure. The V-HeFT Studies. The V-HeFT VA Cooperative Studies Group. Circulation 87(6 Suppl.), VI102-VI110 (1993) (Pubitemid 23164229)
58. Dries DL, Exner DV, Gersh BJ, Domanski MJ, Waclawiw MA, Stevenson LW. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol. 32(3), 695-703 (1998) (Pubitemid 28435256)
59. Rivero-Ayrza M, Scholte op Reimer W, Lenzen M et al. New-onset atrial fibrillation is an independent predictor of in-hospital mortality in hospitalized heart failure patients: results of the EuroHeart Failure Survey. Eur Heart J. 29, 1618-1624 (2008) (Pubitemid 351957546)
60. Mathew J, Hunsberger S, Fleg J, Mc Sherry F, Williford W, Yusuf S. Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. Chest 118(4), 914-922 (2000)
61. Wang TJ, Larson MG, Levy D et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 107, 2920-2935 (2003)